Subscribe
shutterstock_1889776960_giovanni_cancemi
Giovanni Cancemi / Shutterstock.com
8 June 2023Big PharmaMarisa Woutersen

Moderna, Pfizer and BioNTech hit with COVID-19 vaccine lawsuits over mRNA tech

Promosome claimed it shared mRNA tech with the trio, who went on to make hugely successful vaccines | The small biotech wants a cut of more than $100 billion allegedly made by the big pharma companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Moderna and Pfizer face fresh suits over COVID-19 vaccine
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Biotechnology
Pfizer faces infringement suit over COVID-19 vaccine
6 April 2023   Arbutus and Genevant claims Pfizer/BioNTech vaccine uses patented technology | Claim follows last year’s lawsuit against Moderna.
Big Pharma
BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Moderna and Pfizer face fresh suits over COVID-19 vaccine
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Biotechnology
Pfizer faces infringement suit over COVID-19 vaccine
6 April 2023   Arbutus and Genevant claims Pfizer/BioNTech vaccine uses patented technology | Claim follows last year’s lawsuit against Moderna.
Big Pharma
BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

More on this story

Big Pharma
Moderna and Pfizer face fresh suits over COVID-19 vaccine
30 May 2023   A US biotech is accusing the pair of infringing several of its “foundational” lipid particle patents | Pfizer and BioNTech accused plaintiff in earlier suit of antitrust in a dispute over one of the patents at issue.
Biotechnology
Pfizer faces infringement suit over COVID-19 vaccine
6 April 2023   Arbutus and Genevant claims Pfizer/BioNTech vaccine uses patented technology | Claim follows last year’s lawsuit against Moderna.
Big Pharma
BioNTech and Pfizer challenge Moderna’s COVID-19 vaccine patent
29 August 2023   Inter partes review challenges broad claims and monopolisation over mRNA tech amidst existing legal dispute | Alnylam set to appeal separate court ruling against Moderna.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York